What are Myriad Genetics's total assets?

Myriad Genetics (MYGN) holds $673.7M in total assets, down 33.0% year over year.

How much debt does Myriad Genetics have?

Myriad Genetics carries $211.5M in total debt against $337.4M of shareholders' equity, a debt-to-equity ratio of 0.63.

How much cash does Myriad Genetics have?

Myriad Genetics holds $126.0M in cash and equivalents.

Can Myriad Genetics cover its short-term obligations?

Its current ratio is 2.40 — current assets exceed current liabilities.

Where does Myriad Genetics's balance sheet data come from?

Every line is extracted from Myriad Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Myriad Genetics MYGN Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$151.3M+35.2%	$111.9M-20.6%	$140.9M+112%	$66.4M-74.3%
Restricted cash	——	——	——	——
Accounts receivable, net	$115.3M-4.9%	$121.2M+6.0%	$114.3M+12.5%	$101.6M+11.3%
Inventories	$30.6M+11.3%	$27.5M+25.0%	$22M+9.5%	$20.1M+31.4%
Prepaid expenses and other current assets	$25.1M-17.7%	$30.5M+57.2%	$19.4M-4.9%	$20.4M-2.9%
Income taxes receivable	$12M-26.8%	$16.4M-3.5%	$17M-3.4%	$17.6M-4.3%
Total current assets	$332.6M+11.6%	$298M-5.0%	$313.6M+14.2%	$274.6M-43.4%
Property and equipment, net	$114M-2.9%	$117.4M-1.3%	$119M+42.7%	$83.4M+91.7%
Accumulated depreciation	$87.9M-19.8%	$109.6M-8.6%	$119.9M+9.8%	$109.2M+2.2%
Operating lease right-of-use assets	$49.4M-10.2%	$55M-10.7%	$61.6M-40.7%	$103.9M+27.0%
Goodwill	$51.6M-82.0%	$286.3M-0.4%	$287.4M+0.2%	$286.8M+19.9%
Intangible assets, net	$153.4M-41.5%	$262.4M-24.9%	$349.5M-8.0%	$379.7M-6.0%
Other non-current assets	$5.6M-34.1%	$8.5M-44.8%	$15.4M-0.6%	$15.5M+86.7%
Total assets	$706.6M-31.2%	$1.03B-10.4%	$1.15B-4.4%	$1.2B-9.2%
Accounts payable	$30M-7.1%	$32.3M+25.2%	$25.8M-10.4%	$28.8M-2.7%
Accrued expenses	$51.2M-57.0%	$119M+4.5%	$113.9M+20.8%	$94.3M-41.7%
Operating lease liabilities, current	$6.9M-46.1%	$12.8M-21.0%	$16.2M+14.9%	$14.1M+8.5%
Income taxes payable	$5.7M+11.8%	$5.1M+10.9%	$4.6M-4.2%	$4.8M+20.0%
Total current liabilities	$133.8M-18.5%	$164.1M+5.3%	$155.9M+13.6%	$137.2M-32.8%
Long-term debt	$119.9M+203%	$39.6M+2.9%	$38.5M—	$0—
Operating lease liabilities, non-current	$83M-5.6%	$87.9M-9.8%	$97.4M-25.6%	$130.9M+65.1%
Operating Lease Liabilities (Total)	$89.9M-10.7%	$100.7M—	——	——
Other non-current liabilities	$1.9M-13.6%	$2.2M-94.7%	$41.3M+129%	$18M+221%
Total liabilities	$338.6M+3.7%	$326.5M-10.1%	$363.3M+16.1%	$312.9M-11.3%
Common stock	900K0.0%	900K0.0%	900K+12.5%	800K0.0%
Additional paid-in capital	$1.49B+2.1%	$1.46B+3.0%	$1.42B+12.3%	$1.26B+2.8%
Retained earnings	-$1.12B-48.3%	-$756.8M-20.2%	-$629.5M-71.9%	-$366.2M-44.1%
Accumulated other comprehensive income (loss)	$800K+200%	-$800K+78.4%	-$3.7M+58.4%	-$8.9M-74.5%
Total stockholders' equity	$368M-47.5%	$701.1M-10.5%	$783.2M-11.6%	$885.8M-8.5%
Total liabilities and stockholders' equity	$706.6M-31.2%	$1.03B-10.4%	$1.15B-4.4%	$1.2B-9.2%
Deferred Tax Assets and Other Non-Current Assets	$5.6M-34.1%	$8.5M-44.8%	$15.4M-0.6%	$15.5M+86.7%
Finite Lived Intangible Assets - Gross	$511.9M-13.4%	$591.2M-8.5%	$645.8M—	——
Net Investment in Lease	$49.4M-10.2%	$55M-10.7%	$61.6M-40.7%	$103.9M+27.0%
Intangible assets — net	$153.4M-41.5%	$262.4M-24.9%	$349.5M—	——
Other intangible assets—net	$153.4M-41.5%	$262.4M-24.9%	$349.5M-8.0%	$379.7M-6.0%
Operating lease right-of-use assets	$49.4M-10.2%	$55M-10.7%	$61.6M-40.7%	$103.9M+27.0%
Other non-current assets	$5.6M-34.1%	$8.5M-44.8%	$15.4M-0.6%	$15.5M+86.7%
Property, plant and equipment at cost	$201.9M-11.1%	$227M-5.0%	$238.9M+24.0%	$192.6M+28.1%
Operating Lease Right-of-Use Assets in Other Assets	$49.4M-10.2%	$55M-10.7%	$61.6M-40.7%	$103.9M+27.0%
Software and Technology Licenses, Net	$5.6M-34.1%	$8.5M-44.8%	$15.4M-0.6%	$15.5M+86.7%
Accrued Manufacturing Costs	$51.2M-10.8%	$57.4M+15.5%	$49.7M+20.6%	$41.2M-22.0%
Accrued Royalties (Current)	$4.7M-27.7%	$6.5M+22.6%	$5.3M+10.4%	$4.8M-11.1%
Other Commercial Liabilities	$96.9M-18.6%	$119M+4.5%	$113.9M+20.8%	$94.3M-41.7%
Accrued Liabilities, Current	$96.9M-18.6%	$119M+4.5%	$113.9M+20.8%	$94.3M-41.7%
Compensation and benefits	$51.2M-10.8%	$57.4M+15.5%	$49.7M+20.6%	$41.2M-22.0%
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$8.9M—	——	——	——
Total debt	$209.8M+49.5%	$140.3M-7.8%	$152.1M+4.9%	$145M+57.1%
Total Carrying Value of Debt	$125M—	——	——	——
Common Stock Par Value Per Share	——	——	——	——
Common Stock Shares Issued	93.5M+2.4%	91.3M+1.6%	89.9M+10.7%	81.2M+1.5%
Convertible Preferred Stock Authorized Shares	——	——	——	——
Convertible Preferred Stock Outstanding Shares	——	——	——	——
Additional paid-in capital	$1.49B+2.1%	$1.46B+3.0%	$1.42B+12.3%	$1.26B+2.8%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$900K0.0%	$900K0.0%	$900K+12.5%	$800K0.0%
Number of Exercisable Options	——	——	——	——
Preferred Stock Par Value Per Share	——	——	——	——
Share-Based Payment Award Options Outstanding - Number	700K0.0%	700K0.0%	700K0.0%	700K-50.0%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$13.380.0%	$13.380.0%	$13.380.0%	$13.38-34.3%
Cumulative Cost Basis	$201.9M-11.1%	$227M-5.0%	$238.9M+24.0%	$192.6M+28.1%
Accrued exit fee	$3.8M—	——	——	——
Licensing Arrangements	$4.7M-27.7%	$6.5M+22.6%	$5.3M+10.4%	$4.8M-11.1%
Common stock, par value (in dollars per share)	——	——	——	——
Common stock, shares authorized (in shares)	——	——	——	——
Common stock, shares issued (in shares)	$93.5M+2.4%	$91.3M+1.6%	$89.9M+10.7%	$81.2M+1.5%
Common Stock, Shares, Outstanding	$93.5M+2.4%	$91.3M+1.6%	$89.9M+10.7%	$81.2M+1.5%
Long-term debt, gross	$125M—	——	——	——
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net	$8.9M—	——	——	——
Cost not yet recognized	——	——	——	——
Finite-Lived Intangible Assets, Accumulated Amortization	$358.5M+9.0%	$328.8M+11.0%	$296.3M+17.1%	$253M+19.1%
Gross Carrying Amount	$511.9M-13.4%	$591.2M-8.5%	$645.8M—	——
Other accrued liabilities	$15.4M-31.9%	$22.6M+9.2%	$20.7M-14.5%	$24.2M+25.4%
Preferred Stock, Par or Stated Value Per Share	——	——	——	——
Preferred Stock, Shares Authorized	——	——	——	——
Preferred Stock, Shares Outstanding	——	——	——	——
Refunds payable and reserves	$19.9M0.0%	$19.9M-1.0%	$20.1M+4.1%	$19.3M+96.9%
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$700K0.0%	$700K0.0%	$700K0.0%	$700K-50.0%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$13.380.0%	$13.380.0%	$13.380.0%	$13.38-34.3%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Myriad Genetics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Myriad Genetics's total assets?: Myriad Genetics (MYGN) holds $673.7M in total assets, down 33.0% year over year.
How much debt does Myriad Genetics have?: Myriad Genetics carries $211.5M in total debt against $337.4M of shareholders' equity, a debt-to-equity ratio of 0.63.
How much cash does Myriad Genetics have?: Myriad Genetics holds $126.0M in cash and equivalents.
Can Myriad Genetics cover its short-term obligations?: Its current ratio is 2.40 — current assets exceed current liabilities.
Where does Myriad Genetics's balance sheet data come from?: Every line is extracted from Myriad Genetics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.